Ibandronate for the prevention of nonvertebral fractures: A pooled analysis of individual patient data

Osteoporosis International

Volumn 20, Issue 2, 2009, Pages 291-297

  Cranney, A ^a   Wells, G A ^b   Yetisir, E ^b   Adami, S ^c   Cooper, C ^d   Delmas, P D ^e   Miller, P D ^f   Papapoulos, S ^g   Reginster, J Y ^h   Sambrook, P N ⁱ   Silverman, S ^j   Siris, E ^k   Adachi, J D ^l  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITÉ DE LYON   (France)

^f University of Colorado Health Sciences Center   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF LIÈGE   (Belgium)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k Columbia University ^*  (United States)

^l MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

Ibandronate; Nonvertebral fractures; Postmenopausal osteoporosis

Indexed keywords

IBANDRONIC ACID; PLACEBO;

ADULT; ARTICLE; BONE DENSITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; FRACTURE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; PATIENT CODING; POSTMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; THERAPY EFFECT;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 58149465376     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0653-8     Document Type: Article

References (15)

1. CH Chesnut III A Skag C Christiansen R Recker JA Stakkestad A Hoiseth 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 8 1241 1249
2. R Recker JA Stakkestad CH Chesnut III C Christiansen A Skag A Hoiseth 2004 Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis Bone 34 5 890 899
3. PD Miller MR McClung L Macovei JA Stakkestad M Luckey B Bonvoisin 2005 Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res 20 8 1315 1322
4. PD Delmas S Adami C Strugala JA Stakkestad JY Reginster D Felsenberg 2006 Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study Arthritis Rheum 54 6 1838 1846
5. P Ravn G Neugebauer C Christiansen 2002 Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis Bone 30 1 320 324
6. S Adami D Felsenberg C Christiansen J Robinson RS Lorenc P Mahoney 2004 Efficacy and safety of ibandronate given by intravenous injection once every 3 months Bone 34 5 881 889
7. BJ Riis J Ise T von Stein Y Bagger C Christiansen 2001 Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis J Bone Miner Res 16 10 1871 1878
8. D Thiebaud P Burckhardt H Kriegbaum H Huss H Mulder JR Juttmann 1997 Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis Am J Med 103 4 298 307
9. PD Delmas RR Recker CH Chesnut III A Skag JA Stakkestad R Emkey 2004 Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study Osteoporos Int 15 10 792 798
10. JY Reginster S Adami P Lakatos M Greenwald JJ Stepan SL Silverman 2006 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study Ann Rheum Dis 65 5 654 661
11. J Barrett E Worth F Bauss S Epstein 2004 Ibandronate: a clinical pharmacological and pharmacokinetic update J Clin Pharm 44 9 951 965
12. SC Cremers G Pillai SE Papapoulos 2005 Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimization of intermittent therapy for osteoporosis Clin Pharmacokinet 44 6 551 570
13. SE Papapoulos RC Schimmer 2007 Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate Ann Rheum Dis 66 7 853 858
14. JT Harrington LG Ste-Marie ML Brandi R Civitelli P Fardellone A Grauer 2004 Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int 74 2 129 135
15. SE Papapoulos SA Quandt UA Liberman MC Hochberg DE Thompson 2005 Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Osteoporos Int 16 5 468 474